Y230 Stock Overview
Through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Akanda Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.24 |
| 52 Week High | US$39.20 |
| 52 Week Low | US$1.10 |
| Beta | 1.52 |
| 11 Month Change | -24.51% |
| 3 Month Change | -42.69% |
| 1 Year Change | -96.05% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| Y230 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -0.2% | -5.0% | -1.3% |
| 1Y | -96.1% | -22.0% | 7.4% |
Return vs Industry: Y230 underperformed the German Pharmaceuticals industry which returned -22% over the past year.
Return vs Market: Y230 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| Y230 volatility | |
|---|---|
| Y230 Average Weekly Movement | 19.1% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Y230's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Y230's weekly volatility has decreased from 43% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Katie Field | www.akandacorp.com |
Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products for medicinal use worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.
Akanda Corp. Fundamentals Summary
| Y230 fundamental statistics | |
|---|---|
| Market cap | €1.84m |
| Earnings (TTM) | -€30.58m |
| Revenue (TTM) | €2.41m |
0.8x
P/S Ratio-0.1x
P/E RatioIs Y230 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Y230 income statement (TTM) | |
|---|---|
| Revenue | US$2.51m |
| Cost of Revenue | US$2.25m |
| Gross Profit | US$259.56k |
| Other Expenses | US$32.10m |
| Earnings | -US$31.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -22.32 |
| Gross Margin | 10.35% |
| Net Profit Margin | -1,269.38% |
| Debt/Equity Ratio | 7.8% |
How did Y230 perform over the long term?
See historical performance and comparison